1000/1000
Hot
Most Recent
Human epidermal growth factor receptor-2 (HER2) is a well-known target for approximately 15% of gastric adenocarcinomas (GACs). Although a plethora of HER2-targeted agents are marketed, currently only two agents are approved for GAC. These two agents are used only in the metastatic setting. Trastuzumab is utilized in combination with front-line chemotherapy, and trastuzumab deruxtecan is given following failure of trastuzumab therapy.
Drug Name | HER2 bsAb | Trial Number | Phase | Population |
---|---|---|---|---|
RC48 | Anti-HER2 + MMAE | NCT04714190 NCT05514158 NCT05982834 |
3 1 1/2 |
Locally advanced/metastatic HER2 GAC Locally advanced/metastatic HER2 GAC Metastatic HER2 GAC |
ZW49 | Anti-HER2 bsAb (ZW25) + Auristatin | NCT03821233 | 1 | Advanced HER2-expressing cancers |
MRG002 | Anti-HER2 IgG1 + MMAE | NCT04492488 NCT05141747 |
1 2 |
Advanced HER2 solid tumors Locally advanced/metastatic HER2-positive/HER2 low GAC |
FS-1502 | Anti-HER2 + MMAF | NCT03944499 | 1 | HER2-positive advanced breast or solid tumors |
GQ1001 | Anti-HER2 + DM1 | NCT04450732 | 1 | HER2-positive advanced solid tumors |
ARX788 | Modified Trastuzumab + MMAF | NCT03255070 | 1 | HER2-positive advanced solid tumors |
BDC-1001 | Trastuzumab biosimilar + TLR7/8 agonist | NCT04278144 | 1/2 | HER2-positive advanced solid tumors |